Chimeric antigen receptors with BCMA specificity and uses thereof

Patent metadata

Field	Value
Publication number	US-12150959-B2
Application number	US-201916516060-A
Country	US
Kind code	B2
Filing date	Jul 18, 2019
Priority date	Jul 19, 2018
Publication date	Nov 26, 2024
Grant date	Nov 26, 2024

Abstract

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

First claim

What is claimed is:

1. A B-cell maturation antigen (BCMA)-specific chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand-binding domain comprising an anti-BCMA antigen-binding domain; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a costimulatory domain and a signaling domain, wherein the extracellular ligand-binding domain comprises an anti-BCMA single chain variable fragment (scFv) domain comprising a light chain variable region (LCVR) comprising complementarity determining regions LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences, respectively, of SEQ ID NOs: 60, 62, and 64, and a heavy chain variable region (HCVR) comprising complementarity determining regions HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences, respectively, of SEQ ID NOs: 52, 54, and 56.

2. The chimeric antigen receptor of claim 1 , wherein the anti-BCMA scFv domain comprises a linker between the LCVR and the HCVR.

3. The chimeric antigen receptor of claim 1 ,
further comprising a linker between the extracellular ligand-binding domain and the hinge.

4. The chimeric antigen receptor of claim 1 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 58, and the HCVR comprises the amino acid sequence of SEQ ID NO: 50.

5. The chimeric antigen receptor of claim 1 , comprising the amino acid sequence of SEQ ID NO: 88.

6. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1 .

7. A vector comprising the nucleic acid molecule of claim 6 .

8. A cell comprising the isolated nucleic acid molecule of claim 6 .

9. An engineered cell comprising a chimeric antigen receptor of claim 1 .

10. The engineered cell of claim 9 that is an immune cell.

11. An engineered human T cell comprising a chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand-binding domain comprising an anti-BCMA single chain variable fragment (scFv) domain comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR); (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a 4-1BB costimulatory domain and a CD3zeta signaling domain, wherein the LCVR of the anti-BCMA scFv domain comprises complementarity determining regions LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences, respectively, of SEQ ID NOs: 60, 62, and 64, and the HCVR of the anti-BCMA scFv domain comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences, respectively, of SEQ ID NOs: 52, 54, and 56.

12. The engineered human T cell of claim 11 , wherein the scFv domain comprises a LCVR/HCVR amino acid sequence pair comprising the amino acid sequences of SEQ ID NOs: 58/50.

13. The engineered human T cell of claim 11 :
(a) wherein the hinge comprises the amino acid sequence of SEQ ID NO: 97;
(b) wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 98;
(c) wherein the 4-1BB costimulatory domain comprises the amino acid sequence of SEQ ID NO: 99; or
(d) wherein the CD3zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 100.

14. The engineered human T cell of claim 11 , comprising a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 88.

15. A pharmaceutical composition comprising a genetically-modified human T cell and a pharmaceutically acceptable carrier, wherein the genetically-modified human T cell comprises a chimeric antigen receptor according to claim 1 .

16. A method of engineering a population of cells to express a chimeric antigen receptor, comprising:
(a) providing a population of immune cells;
(b) introducing into the immune cells a nucleic acid molecule encoding a chimeric antigen receptor of claim 1 ;
(c) culturing the immune cells under conditions to express the nucleic acid molecules; and
(d) isolating the immune cells expressing the chimeric antigen receptor at the cells' surface.

17. The method of claim 16 , further comprising obtaining the population of immune cells from a subject prior to introducing the nucleic acid molecule.

18. The isolated nucleic acid molecule of claim 6 , comprising the nucleotide sequence of SEQ ID NO: 87.

19. The vector of claim 7 , wherein the vector is a DNA vector, an RNA vector, a plasmid, a lentivirus vector, an adenovirus vector, or a retroviral vector.

20. The cell of claim 8 , wherein the cell is a human T cell.

21. The engineered cell of claim 9 , wherein the immune cell is an immune effector cell, a T lymphocyte, an inflammatory T lymphocyte, a cytotoxic T lymphocyte, a regulatory T lymphocyte, a helper T lymphocyte, or a CD8+cytotoxic T lymphocyte.

22. The chimeric antigen receptor of claim 2 , wherein the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 93-96.

23. The chimeric antigen receptor of claim 22 , wherein the linker comprises the amino acid sequence of SEQ ID NO: 95.

24. The chimeric antigen receptor of claim 1 :
(a) wherein the hinge, the transmembrane domain, or both, are from a CD8a polypeptide;
(b) wherein the costimulatory domain comprises a 4-1BB costimulatory domain;
or
(c) wherein the signaling domain comprises a CD3zeta signaling domain.

25. The chimeric antigen receptor of claim 24 :
(a) wherein the hinge comprises the amino acid sequence of SEQ ID NO: 97;
(b) wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 98;
(c) wherein the 4-1BB costimulatory domain comprises the amino acid sequence of SEQ ID NO: 99; or
(d) wherein the CD3zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 100.

Assignees

• Regeneron Pharma

Inventors

• Dilillo David
• Delfino Frank
• Bray Kevin
• Meagher Thomas Craig
• Kirshner Jessica
• Sineshchekova Olga

Classifications

• A61K40/4215

  Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title